Uncategorized
Novel molecule shows promise for future treatment of neovascular AMD
SAN DIEGO — Higher doses of a novel small molecule underdevelopment offers potential as a future treatment for neovascular age-relatedmacular degeneration, according to early results of a phase 2 dose-escalationstudy. Pravin U. Dugel,MD, told colleagues at the American Society of Retina Specialists annualmeeting that ESBA 1008 met its primary endpoint of noninferiority at week 4 vs.ranibizumab (Lucentis, Genentech) in two of its highest doses being assessedfor safety and tolerability.